BG105097A - Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders - Google Patents

Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders

Info

Publication number: BG105097A
Authority: BG; Bulgaria
Prior art keywords: apnea; disorders; norcisapride; bulimia; treatment
Prior art date: 1998-06-15

Application number

BG105097A

Other languages

Bulgarian (bg)

English (en)

Inventor

Paul Rubin

Timothy Barberich

Original Assignee

Sepracor, Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-15

Filing date

2000-12-27

Publication date

2002-02-28

2000-12-27 Application filed by Sepracor, Inc filed Critical Sepracor, Inc

2002-02-28 Publication of BG105097A publication Critical patent/BG105097A/xx

Links

208000008784 apnea Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
208000032841 Bulimia Diseases 0.000 title abstract 2
206010006550 Bulimia nervosa Diseases 0.000 title abstract 2
OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 title abstract 2
208000006218 bradycardia Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
206010049765 Bradyarrhythmia Diseases 0.000 abstract 1
206010046543 Urinary incontinence Diseases 0.000 abstract 1
230000036471 bradycardia Effects 0.000 abstract 1
208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1
206010042772 syncope Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)

BG105097A 1998-06-15 2000-12-27 Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders BG105097A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8922598P	1998-06-15	1998-06-15
US12223699P	1999-03-01	1999-03-01
PCT/US1999/013100 WO1999065490A2 (en)	1998-06-15	1999-06-10	Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders

Publications (1)

Publication Number	Publication Date
BG105097A true BG105097A (en)	2002-02-28

Family

ID=26780367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105097A BG105097A (en)	1998-06-15	2000-12-27	Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders

Country Status (24)

Country	Link
US (2)	US6559165B1 (cs)
EP (1)	EP1087765B1 (cs)
JP (1)	JP2003522103A (cs)
KR (3)	KR20060067985A (cs)
CN (1)	CN1312716A (cs)
AR (1)	AR020327A1 (cs)
AT (1)	ATE291916T1 (cs)
AU (1)	AU764474B2 (cs)
BG (1)	BG105097A (cs)
BR (1)	BR9911302A (cs)
CA (1)	CA2334369A1 (cs)
CZ (1)	CZ20004736A3 (cs)
DE (1)	DE69924488T2 (cs)
ES (1)	ES2237117T3 (cs)
HK (1)	HK1040059A1 (cs)
HU (1)	HUP0102026A3 (cs)
IL (1)	IL140117A0 (cs)
IS (1)	IS5755A (cs)
NO (1)	NO20006358L (cs)
NZ (3)	NZ535055A (cs)
PL (1)	PL345325A1 (cs)
SK (1)	SK19062000A3 (cs)
TR (6)	TR200103759T2 (cs)
WO (1)	WO1999065490A2 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7160898B2 (en)	2001-12-14	2007-01-09	Board Of Trustees Of The University Of Illinois	Pharmacological treatment for sleep apnea
US6362202B1 (en) *	1999-03-02	2002-03-26	Sepracor Inc.	Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6663639B1 (en)	1999-06-22	2003-12-16	Ndo Surgical, Inc.	Methods and devices for tissue reconfiguration
US7846180B2 (en)	1999-06-22	2010-12-07	Ethicon Endo-Surgery, Inc.	Tissue fixation devices and methods of fixing tissue
US6821285B2 (en)	1999-06-22	2004-11-23	Ndo Surgical, Inc.	Tissue reconfiguration
US6835200B2 (en)	1999-06-22	2004-12-28	Ndo Surgical. Inc.	Method and devices for tissue reconfiguration
US8287554B2 (en)	1999-06-22	2012-10-16	Ethicon Endo-Surgery, Inc.	Method and devices for tissue reconfiguration
CA2590802A1 (en)	2004-12-20	2006-06-29	Collegium Pharmaceutical, Inc.	Pharmaceutical compositions for sleep disorders
GB0524668D0 (en) *	2005-12-02	2006-01-11	Novartis Ag	Organic compounds
US8852216B2 (en)	2007-03-23	2014-10-07	Ethicon Endo-Surgery, Inc.	Tissue approximation methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR748807A (fr)	1932-03-10	1933-07-10	Gulf Refining Co	Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en)	1981-10-01	1985-03-12	Georges Van Daele	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en)	1981-10-01	1992-08-11	Janssen Pharmaceutica N.V.	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en)	1981-10-01	1991-10-15	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en)	1981-10-01	1990-10-09	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4598123A (en)	1983-07-14	1986-07-01	Unites States Steel Corporation	Impact modified methyl methacrylate polymer
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4800162A (en)	1987-04-01	1989-01-24	Sepracor, Inc.	Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en)	1988-04-07	1991-10-15	Sepracor, Inc.	Method for resolution of stereoisomers
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5116407A (en)	1988-10-13	1992-05-26	Courtaulds Coatings Limited	Antifouling coatings
GB8823980D0 (en) *	1988-10-13	1988-11-23	Glaxo Group Ltd	Chemical compounds
JPH02188523A (ja)	1989-01-13	1990-07-24	M S C:Kk	睡眠時無呼吸症治療薬
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en)	1989-06-28	1991-12-24	University Of Virginia Alumni Patents Foundation	Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5356934A (en)	1990-03-29	1994-10-18	Eli Lilly And Company	Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
ATE170747T1 (de) *	1991-12-21	1998-09-15	Smithkline Beecham Plc	Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2139638A1 (en)	1992-07-07	1994-01-20	Nancy M. Gray	Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
AU4770593A (en)	1992-07-07	1994-01-31	Sepracor, Inc.	Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) *	1993-05-25	1993-07-14	Glaxo Lab Sa	Compositions
WO1995001803A1 (en)	1993-07-06	1995-01-19	Merck & Co., Inc.	H2 antagonist-gastrointestinal motility agent combinations
US5502067A (en)	1994-02-04	1996-03-26	Morgan; Julia A.	Treating apneahypopnea/snoring in humans
US5407953A (en)	1994-02-04	1995-04-18	Morgan; Julia A.	Treating apnea/hypopnea/snoring in humans
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5712293A (en) *	1995-06-07	1998-01-27	Sepracor, Inc.	Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) *	1995-06-13	1997-07-11	Synthelabo	Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
BR9811676A (pt) *	1997-07-11	2000-09-19	Janssen Pharmaceutica Nv	(+) norcisaprida útil para distúrbios mediados por 5-ht3 e 5-ht4
IL140118A0 (en)	1998-06-15	2002-02-10	Sepracor Inc	Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders

1999
- 1999-06-10 HK HK02101726.7A patent/HK1040059A1/zh unknown
- 1999-06-10 SK SK1906-2000A patent/SK19062000A3/sk unknown
- 1999-06-10 CZ CZ20004736A patent/CZ20004736A3/cs unknown
- 1999-06-10 CN CN99809564A patent/CN1312716A/zh active Pending
- 1999-06-10 JP JP2000554370A patent/JP2003522103A/ja active Pending
- 1999-06-10 KR KR1020067010978A patent/KR20060067985A/ko not_active Ceased
- 1999-06-10 WO PCT/US1999/013100 patent/WO1999065490A2/en not_active Ceased
- 1999-06-10 KR KR1020007014025A patent/KR20010052740A/ko not_active Ceased
- 1999-06-10 PL PL99345325A patent/PL345325A1/xx not_active Application Discontinuation
- 1999-06-10 CA CA002334369A patent/CA2334369A1/en not_active Abandoned
- 1999-06-10 TR TR2001/03759T patent/TR200103759T2/xx unknown
- 1999-06-10 HU HU0102026A patent/HUP0102026A3/hu unknown
- 1999-06-10 DE DE69924488T patent/DE69924488T2/de not_active Expired - Fee Related
- 1999-06-10 EP EP99930196A patent/EP1087765B1/en not_active Expired - Lifetime
- 1999-06-10 TR TR2000/03707T patent/TR200003707T2/xx unknown
- 1999-06-10 TR TR2001/03760T patent/TR200103760T2/xx unknown
- 1999-06-10 NZ NZ535055A patent/NZ535055A/en unknown
- 1999-06-10 TR TR2001/03762T patent/TR200103762T2/xx unknown
- 1999-06-10 AU AU46784/99A patent/AU764474B2/en not_active Ceased
- 1999-06-10 BR BR9911302-3A patent/BR9911302A/pt not_active Application Discontinuation
- 1999-06-10 KR KR1020067003048A patent/KR20060020739A/ko not_active Ceased
- 1999-06-10 IL IL14011799A patent/IL140117A0/xx unknown
- 1999-06-10 TR TR2001/03757T patent/TR200103757T2/xx unknown
- 1999-06-10 TR TR2001/03758T patent/TR200103758T2/xx unknown
- 1999-06-10 ES ES99930196T patent/ES2237117T3/es not_active Expired - Lifetime
- 1999-06-10 AT AT99930196T patent/ATE291916T1/de not_active IP Right Cessation
- 1999-06-10 NZ NZ526108A patent/NZ526108A/en unknown
- 1999-06-15 AR ARP990102864A patent/AR020327A1/es unknown
2000
- 2000-11-28 US US09/722,391 patent/US6559165B1/en not_active Expired - Fee Related
- 2000-12-08 IS IS5755A patent/IS5755A/is unknown
- 2000-12-12 NZ NZ508825A patent/NZ508825A/en unknown
- 2000-12-13 NO NO20006358A patent/NO20006358L/no unknown
- 2000-12-27 BG BG105097A patent/BG105097A/xx unknown
2003
- 2003-02-26 US US10/372,875 patent/US7064138B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ535055A (en)	2006-04-28
US7064138B2 (en)	2006-06-20
BR9911302A (pt)	2001-03-13
TR200103758T2 (tr)	2002-06-21
DE69924488D1 (de)	2005-05-04
US6559165B1 (en)	2003-05-06
JP2003522103A (ja)	2003-07-22
TR200103759T2 (tr)	2002-06-21
HK1040059A1 (zh)	2002-05-24
WO1999065490A3 (en)	2000-04-13
TR200103760T2 (tr)	2002-06-21
ES2237117T3 (es)	2005-07-16
CN1312716A (zh)	2001-09-12
NZ526108A (en)	2004-10-29
KR20010052740A (ko)	2001-06-25
PL345325A1 (en)	2001-12-17
TR200103762T2 (tr)	2002-05-21
IS5755A (is)	2000-12-08
IL140117A0 (en)	2002-02-10
CZ20004736A3 (cs)	2001-09-12
CA2334369A1 (en)	1999-12-23
US20030158229A1 (en)	2003-08-21
AU764474B2 (en)	2003-08-21
DE69924488T2 (de)	2005-09-08
NZ508825A (en)	2003-09-26
AR020327A1 (es)	2002-05-08
HUP0102026A3 (en)	2002-12-28
EP1087765A2 (en)	2001-04-04
TR200103757T2 (tr)	2002-06-21
EP1087765B1 (en)	2005-03-30
TR200003707T2 (tr)	2001-06-21
WO1999065490A2 (en)	1999-12-23
NO20006358L (no)	2001-02-13
HUP0102026A2 (hu)	2001-11-28
KR20060067985A (ko)	2006-06-20
AU4678499A (en)	2000-01-05
NO20006358D0 (no)	2000-12-13
SK19062000A3 (sk)	2001-07-10
ATE291916T1 (de)	2005-04-15
KR20060020739A (ko)	2006-03-06

Publication	Publication Date	Title
BG105096A (en)	2002-02-28	Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders
BE2013C064I2 (cs)	2022-08-09
JO2311B1 (en)	2005-09-12	Alkyl inhibitors Ariel phosphodiesterase-4
PL323825A1 (en)	1998-04-27	Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
EP1695983A3 (en)	2007-02-21	Glucagon-like peptide-1 analogs
MY110110A (en)	1998-01-27	Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
BG102425A (en)	1999-06-30	(methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
MXPA05002442A (es)	2005-09-30	Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
PL316658A1 (en)	1997-02-03	Novel application of serotonin antagonists
AU3111695A (en)	1996-02-16	Substituted pyrimidine compounds and the use thereof
AU2002216218A1 (en)	2002-07-01	Naphthalene derivatives which bind to the ep4 receptor
AU3111395A (en)	1996-02-16	Triazole compounds and the use thereof
AU3111595A (en)	1996-02-16	The use of thiazole and thiadiazole compounds
DE60322417D1 (en)	2008-09-04	4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
IL115589A0 (en)	1996-01-19	Use of cck-b antagonists in pharmaceutical compositions
SG117434A1 (en)	2005-12-29	Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
WO1999065490A3 (en)	2000-04-13	Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
WO2000051582A3 (en)	2001-11-15	Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
AU2634597A (en)	1997-11-12	Compounds with growth hormone releasing properties
WO2000010554A3 (en)	2000-11-30	Methods and compositions employing optically pure s(+) vigabatrin
AU9157698A (en)	1999-02-22	Piperazine derivatives active on the lower urinary tract
GB2389532A (en)	2003-12-17	The method of treating cancer
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
NO990450L (no)	1999-01-29	Behandling av sinnslidelser
DE60009315D1 (de)	2004-05-13	Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung